Abhijeet Dhoble
Interventional Cardiology · Houston, TXNPI 1407048549
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Abbott at 57.8% of the total. Reporting peaked in 2020 at $45,950 and has fallen 60.4% since, to $18,205 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 476 payments — averaging $337.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$93K
- Edwards Lifesciences$42K
- Medtronic$13K
- Boston Scientific$7K
- Canon Medical Systems USA, Inc.$4K
- W. L. Gore & Associates, Inc.$664
- plus $2K from 11 others
Across 250 payments — averaging $10,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$1.4M
- Boston Scientific$922K
- Abbott$152K
- Medtronic$59K
- Cathworks, Inc.$10K
What the payments were for
- Consulting fees$83,29552%
- Speaking & faculty fees$37,71923%
- Travel & lodging$17,66711%
- Food & beverage$21,67513%
- Education$3990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 207 | $92,892 |
| Edwards Lifesciences | 98 | $41,737 |
| Medtronic(2 entities) | 116 | $13,236 |
| Boston Scientific | 22 | $6,627 |
| Canon Medical Systems USA, Inc. | 3 | $4,024 |
| W. L. Gore & Associates, Inc. | 8 | $664 |
| Endologix LLC | 1 | $338 |
| Angiodynamics, Inc. | 4 | $325 |
| Abiomed | 2 | $289 |
| Teleflex LLC | 6 | $262 |
| Biotronik Inc. | 2 | $132 |
| Shockwave Medical, Inc | 1 | $69 |
| Arrow International, Inc. | 2 | $42 |
| Cardiva Medical, Inc. | 1 | $37 |
| Novartis | 1 | $29 |
| Cardiac Dimensions, Inc. | 1 | $29 |
| AstraZeneca | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$36,722
- AMPLATZER Occluders$27,660
- Edwards SAPIEN 3 Transcatheter Heart Valve$16,207
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$12,500
- MitraClip$11,745
- GENERAL - THERAPIES$6,040
- AMPLATZER AMULET$5,726
- COREVALVE EVOLUT R$4,689
- INTERVENTIONAL ANGIOGRAPHY SYSTEM$4,000
- AMPLATZER$3,962
- CoreValve Evolut$2,153
- SAPIEN 3 Ultra RESILIA$1,505
- APOLLOTM$1,422
- Resolute$1,361
- AMPLATZER PICCOLO$1,050
- ADVISOR$712
- TENDYNE$652
- GORE CARDIOFORM Septal Occluder$572
- NAVITOR$463
- MitraClip System$446
How this compares
$160,754 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 143 | $140,702 |
| EntrestoSacubitril/Valsartan | 80 | $87,281 |
| JardianceEmpagliflozin | 60 | $68,919 |
| XareltoRivaroxaban | 62 | $54,198 |
| Repatha SureclickEvolocumab | 22 | $17,520 |
| BrilintaTicagrelor | 18 | $12,338 |
| FarxigaDapagliflozin Propanediol | 13 | $6,175 |
| Metoprolol Succinate | 255 | $3,673 |
| Ranolazine ErRanolazine | 49 | $3,098 |
| Nifedipine ErNifedipine | 80 | $2,040 |
| Losartan Potassium | 184 | $1,686 |
| Atorvastatin Calcium | 177 | $1,193 |
| ClopidogrelClopidogrel Bisulfate | 148 | $1,059 |
| Lisinopril | 109 | $812 |
| Rosuvastatin Calcium | 51 | $794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $29 | $87,28180 claims |
| AstraZenecaBrilinta, Farxiga | $22 | $18,51331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
- Salman ArainHouston$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.